Skip to main content
Caplight Logo









iCell Gene Therapeutics

iCell Gene Therapeutics

Private
Stony Brook, New YorkHealthcare & Life Scienceshttps://www.icellgene.com/

Last Round

Grant

Oct 8, 2020

Total Funding Raised

$3.1M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

iCell Gene Therapeutics is a biotechnology company that develops chimeric antigen receptor (CAR) immunotherapies for the treatment of autoimmune diseases and cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

CAR-T therapycell therapycompound CARcCARautoimmune disease treatmentcancer immunotherapyCAR-NKbiotechnologyclinical trialsdrug developmentnext-gen CARliving drugsprecision medicineviral vector manufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

iCell Gene Therapeutics Comparables

Compare iCell Gene Therapeutics with similar companies based on industry and business-model similarity.

iCell Gene Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Luminary Therapeutics, Inc.
82%
AstraZeneca
81%
Lyell Immunopharma
77%

iCell Gene Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 8, 2020

Key People

Founding team and executive leadership

Timothy E. Morris

Chief Financial Officer

Executive Team

iCell Gene Therapeutics Investors

Notable investors and investment history

iCell Gene Therapeutics investors
InvestorRounds
Long Island High Technology IncubatorAccelerator
Food and Drug AdministrationGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 2, 2026

    Grew 27% QoQ from 11 to 14 employees.

  • May 19, 2026

    Monthly visitors grew 33% MoM, reaching 961.

iCell Gene Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

iCell Gene Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about iCell Gene Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersStony Brook, New York
Employee Range14
Year Founded2014
Last FundingOct 8, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?